Pharmaceutical companies in Bangladesh are aggressively offering doctors cash, electronics, and foreign trips in exchange for prescribing their drugs, including substandard or unnecessary ones. This unethical practice is inflating healthcare costs and endangering public health. Experts and regulators warn that many doctors are prioritizing incentives over patients’ wellbeing. Oversight is weak, allowing companies to exploit the system. Reforms are being planned, but enforcement remains limited. Foreign drug companies are exiting the market, unable to compete with these unethical tactics.